vs
Side-by-side financial comparison of CorMedix Inc. (CRMD) and SMITH & WESSON BRANDS, INC. (SWBI). Click either name above to swap in a different company.
CorMedix Inc. is the larger business by last-quarter revenue ($128.6M vs $124.7M, roughly 1.0× SMITH & WESSON BRANDS, INC.). CorMedix Inc. produced more free cash flow last quarter ($92.7M vs $16.3M).
CorMedix Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing novel therapeutic products for the prevention and treatment of infectious, inflammatory and cardiorenal diseases. Its lead candidate targets catheter-related bloodstream infections, serving critical care and chronic dialysis patient populations primarily across North America and European markets.
Smith & Wesson Brands, Inc. (S&W) is an American firearm manufacturer headquartered in Maryville, Tennessee, United States.
CRMD vs SWBI — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $128.6M | $124.7M |
| Net Profit | — | $1.9M |
| Gross Margin | 83.4% | 24.3% |
| Operating Margin | 46.0% | 3.3% |
| Net Margin | — | 1.5% |
| Revenue YoY | — | -3.9% |
| Net Profit YoY | — | -53.6% |
| EPS (diluted) | $0.20 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $128.6M | $124.7M | ||
| Q3 25 | $104.3M | $85.1M | ||
| Q2 25 | $39.7M | $140.8M | ||
| Q1 25 | $39.1M | $115.9M | ||
| Q4 24 | — | $129.7M | ||
| Q3 24 | — | $88.3M | ||
| Q2 24 | — | $159.1M | ||
| Q1 24 | — | $137.5M |
| Q4 25 | — | $1.9M | ||
| Q3 25 | $108.6M | $-3.4M | ||
| Q2 25 | $19.8M | $8.6M | ||
| Q1 25 | $20.6M | $2.1M | ||
| Q4 24 | — | $4.5M | ||
| Q3 24 | — | $-1.9M | ||
| Q2 24 | — | $27.9M | ||
| Q1 24 | — | $7.9M |
| Q4 25 | 83.4% | 24.3% | ||
| Q3 25 | 89.3% | 25.9% | ||
| Q2 25 | 95.3% | 28.8% | ||
| Q1 25 | 95.9% | 24.1% | ||
| Q4 24 | — | 26.6% | ||
| Q3 24 | — | 27.4% | ||
| Q2 24 | — | 35.5% | ||
| Q1 24 | — | 28.7% |
| Q4 25 | 46.0% | 3.3% | ||
| Q3 25 | 49.2% | -3.5% | ||
| Q2 25 | 49.2% | 9.3% | ||
| Q1 25 | 51.5% | 4.1% | ||
| Q4 24 | — | 5.8% | ||
| Q3 24 | — | -1.7% | ||
| Q2 24 | — | 17.4% | ||
| Q1 24 | — | 8.2% |
| Q4 25 | — | 1.5% | ||
| Q3 25 | 104.1% | -4.0% | ||
| Q2 25 | 49.9% | 6.1% | ||
| Q1 25 | 52.8% | 1.8% | ||
| Q4 24 | — | 3.5% | ||
| Q3 24 | — | -2.1% | ||
| Q2 24 | — | 17.5% | ||
| Q1 24 | — | 5.7% |
| Q4 25 | $0.20 | $0.04 | ||
| Q3 25 | $1.26 | $-0.08 | ||
| Q2 25 | $0.28 | $0.19 | ||
| Q1 25 | $0.30 | $0.05 | ||
| Q4 24 | — | $0.10 | ||
| Q3 24 | — | $-0.04 | ||
| Q2 24 | — | $0.60 | ||
| Q1 24 | — | $0.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $148.5M | $22.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $405.3M | $363.2M |
| Total Assets | $826.1M | $548.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $148.5M | $22.4M | ||
| Q3 25 | $55.7M | $18.0M | ||
| Q2 25 | $190.7M | $25.2M | ||
| Q1 25 | $77.5M | $26.7M | ||
| Q4 24 | — | $39.1M | ||
| Q3 24 | — | $35.5M | ||
| Q2 24 | — | $60.8M | ||
| Q1 24 | — | $47.4M |
| Q4 25 | $405.3M | $363.2M | ||
| Q3 25 | $374.1M | $364.4M | ||
| Q2 25 | $220.6M | $372.5M | ||
| Q1 25 | $114.9M | $366.9M | ||
| Q4 24 | — | $371.5M | ||
| Q3 24 | — | $380.0M | ||
| Q2 24 | — | $399.9M | ||
| Q1 24 | — | $376.4M |
| Q4 25 | $826.1M | $548.6M | ||
| Q3 25 | $750.9M | $554.6M | ||
| Q2 25 | $252.6M | $559.6M | ||
| Q1 25 | $149.6M | $578.9M | ||
| Q4 24 | — | $587.4M | ||
| Q3 24 | — | $571.3M | ||
| Q2 24 | — | $577.4M | ||
| Q1 24 | — | $570.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $94.5M | $27.3M |
| Free Cash FlowOCF − Capex | $92.7M | $16.3M |
| FCF MarginFCF / Revenue | 72.1% | 13.1% |
| Capex IntensityCapex / Revenue | 1.3% | 8.8% |
| Cash ConversionOCF / Net Profit | — | 14.22× |
| TTM Free Cash FlowTrailing 4 quarters | $172.8M | $21.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $94.5M | $27.3M | ||
| Q3 25 | $30.9M | $-8.1M | ||
| Q2 25 | $30.0M | $40.8M | ||
| Q1 25 | $19.7M | $-9.8M | ||
| Q4 24 | — | $-7.4M | ||
| Q3 24 | — | $-30.8M | ||
| Q2 24 | — | $43.7M | ||
| Q1 24 | — | $25.2M |
| Q4 25 | $92.7M | $16.3M | ||
| Q3 25 | $30.4M | $-12.4M | ||
| Q2 25 | $30.0M | $33.5M | ||
| Q1 25 | $19.7M | $-16.1M | ||
| Q4 24 | — | $-10.7M | ||
| Q3 24 | — | $-35.5M | ||
| Q2 24 | — | $38.2M | ||
| Q1 24 | — | $7.0M |
| Q4 25 | 72.1% | 13.1% | ||
| Q3 25 | 29.1% | -14.6% | ||
| Q2 25 | 75.4% | 23.8% | ||
| Q1 25 | 50.5% | -13.9% | ||
| Q4 24 | — | -8.3% | ||
| Q3 24 | — | -40.2% | ||
| Q2 24 | — | 24.0% | ||
| Q1 24 | — | 5.1% |
| Q4 25 | 1.3% | 8.8% | ||
| Q3 25 | 0.5% | 5.0% | ||
| Q2 25 | 0.1% | 5.2% | ||
| Q1 25 | 0.0% | 5.4% | ||
| Q4 24 | — | 2.5% | ||
| Q3 24 | — | 5.3% | ||
| Q2 24 | — | 3.5% | ||
| Q1 24 | — | 13.2% |
| Q4 25 | — | 14.22× | ||
| Q3 25 | 0.28× | — | ||
| Q2 25 | 1.51× | 4.73× | ||
| Q1 25 | 0.96× | -4.68× | ||
| Q4 24 | — | -1.63× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 1.57× | ||
| Q1 24 | — | 3.20× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CRMD
| Acquisition Of Melinta | $52.9M | 41% |
| Melinta Portfolio | $45.5M | 35% |
| Other | $18.6M | 14% |
| Contract Revenue | $7.4M | 6% |
| BARDA Agreement | $4.2M | 3% |
SWBI
Segment breakdown not available.
